Pacalis Therapeutics

Pacalis Therapeutics is pioneering the development of next-generation medicines, targeting serotonin signalling in the brain, which plays a crucial role in mood regulation. By combining neuroscience and mental health expertise, high calibre drug discovery capability, and commercialisation, the team is developing a portfolio of best-in-class and first-in-class agents targeting the serotonin (5-HT2A) receptor.

Using state-of-the-art approaches to pharmacology and drug discovery, which has led Monash University to be ranked in the top three worldwide for ‘Pharmacy & Pharmacology’ for the past eight years, the team is working towards the development of differentiated medicines that are more effective and carry fewer side effects than current depression treatments.

The Pacalis team is a blend of industry and academic expertise, led by co-founder and Monash university alumnus Dr David Bibby as Chief Executive Officer, and co-founder Professor Chris Langmead, (Director, Neuromedicines Discovery Centre, Monash University) as Chief Scientific Adviser. Pacalis’ other co-founders include Professor Arthur Christopoulos FAA FAHMS (Dean, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University) and the highly regarded pharmaceutical and biotechnology industry veteran, Dr Warwick Tong, as Director and Chair.

Year established: 2023
Lead Researcher: Professor Chris Langmead
LinkedIn: Pacalis Therapeutics Pty Ltd